Evan David Seigerman
Stock Analyst at BMO Capital
(2.79)
# 2,703
Out of 4,944 analysts
47
Total ratings
39.53%
Success rate
0.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $600 → $640 | $566.76 | +12.92% | 8 | Aug 4, 2025 | |
| REPL Replimune Group | Downgrades: Underperform | $27 → $2 | $5.28 | -62.12% | 4 | Jul 23, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $20.74 | +25.39% | 2 | Jun 12, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $66.90 | +64.42% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $24.64 | +13.64% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $6.86 | +45.77% | 1 | May 5, 2025 | |
| NVO Novo Nordisk | Downgrades: Market Perform | $105 → $64 | $50.51 | +26.72% | 6 | Apr 17, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $83.04 | +15.61% | 4 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $208 → $215 | $203.75 | +5.52% | 7 | Feb 3, 2025 | |
| AMGN Amgen | Maintains: Outperform | $362 → $346 | $289.91 | +19.35% | 4 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $18.72 | +434.19% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $24.90 | +44.58% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $6.15 | -51.22% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $672.21 | -41.09% | 1 | Sep 6, 2022 |
Regeneron Pharmaceuticals
Aug 4, 2025
Maintains: Outperform
Price Target: $600 → $640
Current: $566.76
Upside: +12.92%
Replimune Group
Jul 23, 2025
Downgrades: Underperform
Price Target: $27 → $2
Current: $5.28
Upside: -62.12%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $20.74
Upside: +25.39%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $66.90
Upside: +64.42%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $24.64
Upside: +13.64%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $6.86
Upside: +45.77%
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105 → $64
Current: $50.51
Upside: +26.72%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $83.04
Upside: +15.61%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208 → $215
Current: $203.75
Upside: +5.52%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362 → $346
Current: $289.91
Upside: +19.35%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $18.72
Upside: +434.19%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $24.90
Upside: +44.58%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $6.15
Upside: -51.22%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $672.21
Upside: -41.09%